Trends in the Management of Oligodendrogliomas: A Multinational and Multidisciplinary Survey Study

OBJECTIVE: Oligodendrogliomas present challenges in management despite their favorable prognosis. Optimal therapeutic strategies are not well-established. We aimed to characterize current practice patterns and identify areas of discordance in oligodendroglioma management. METHODS: A20-question survey was distributed FebruaryJuly 2023 to 4 professional neurosurgery/neuro-oncology societiesto assess practices in oligodendroglioma management. The survey collected data on demographics, diagnostic practices, and treatment decisions. Data analysis was performed using chi-square/Fisher's exact tests. RESULTS: Sixty-three physicians responded, representing 12 countries. Diagnostic practices were consistent among mendations were observed. Providers were divided between rarely (36.5%), sometimes (25.4%), and often (30.2%) using temozolomide (TMZ) as sole chemotherapy for patients with newly diagnosed oligodendroglioma. For patients with subtotal resection of grade 2 oligodendroglioma, 33.3% of providers recommended upfront radiation/chemotherapy, 27.0% recommended observation, and the remaining 39.7% were divided among options including surgery, chemotherapy, and clinical trials. European providers more frequently recommended surgery (33.3% vs. 0.0%), whereas radiation/chemotherapy (35.7% vs. 26.7%) or observation (31.0% vs. 13.3%) was more commonly recommended by U.S./Canada providers (P = 0.009). Providers also disagreed on adjuvant therapy for grade 3 oligodendroglioma. 47.6% recommended radiation/procarbazine, lomustine, and vincristine, and 33.3% recommended radiation/TMZ. This decision varied by region, with European providers more frequently recommending radiation/procarbazine, lomustine, and vincristine (86.7% vs. 33.3%) and U.S./ Canadian providers more frequently recommending radiation/ CONCLUSIONS: This study underscores the complexity of oligodendroglioma management and the importance of ongoing research to refine therapeutic strategies. Further studies, especially with the introduction of isocitrate dehydrogenase inhibitors in practice, are warranted to track practice patterns and reassess recommendations.